Myriad Genetics
MYGN
223 hedge funds and large institutions have $1.35B invested in Myriad Genetics in 2016 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 85 increasing their positions, 71 reducing their positions, and 37 closing their positions.
117.94% more ownership
Funds ownership: 0% → 117.94% (+118%)
20% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 71
11% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 37
0% more funds holding
Funds holding: 223 → 223 (0)
20% less capital invested
Capital invested by funds: $1.7B → $1.35B (-$348M)
74% less call options, than puts
Call options by funds: $5.7M | Put options by funds: $22.1M
Top Buyers
Top Sellers
| 1 |
SCM
Scopia Capital Management
New York
|
-$75.3M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$57.5M |
| 3 |
Neuberger Berman Group
New York
|
-$24.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15.3M |
MYGN Hedge Fund Activity: Q4 2016 in Review
223 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2016, worth a combined $1.35B — down 20% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new MYGN positions and 37 closed out — a net gain of 4 holders — while 85 added to existing stakes and 71 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $73.5M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $75.3M sold.
- 223 institutional investors held Myriad Genetics (MYGN) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $1.35B of Myriad Genetics stock for Q4 2016, down 20% quarter-over-quarter.
- 41 funds opened new Myriad Genetics positions in Q4 2016 and 37 closed out, a net change of +4 holders.
- The largest Myriad Genetics buyer in Q4 2016 was Camber Capital Management, an estimated $73.5M added.
- The largest Myriad Genetics seller in Q4 2016 was Scopia Capital Management, an estimated $75.3M sold.
Based on aggregated 13F filings for Q4 2016.